Join the club for FREE to access the whole archive and other member benefits.

ViaCyte

Regenerative medicine company dedicated to developing a functional cure for type 1 diabetes.

ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte’s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.

Visit website: https://viacyte.com/

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

 Login to view link, or join the club to get full access to all resources and other benefits.

ViaCyte News

Looking Back and Ahead in the Use of Pluripotent Stem Cells in Medicine

Fight Aging! - 14-Dec-2016

Therapies that deliver fresh new stem cell populations will take up the work of lost cells, e.g. ...

Read more...

Promising cell therapy for diabetes hidden in seaweed bubble

STAT - 25-Jan-2016

In type 1 diabetes the immune system dismantles the pancreatic cells, known as beta cells, that n...

Read more...